News
The day at a glance · 4 min read
Mood · Mixed
+15
Sentiment, −100 to +100
Amgen Price Target (Citi)
$405
Big Pharma & Biotech
REGN Stock Price
$752.25-4.54%
Big Pharma & Biotech
Small Molecule Market (2024)
$61.5B
Market Research & Industry Trends
Key driverFDA approvals for AbbVie and Eli Lilly offset competitive pressure on Regeneron from positive Phase 3 ophthalmology data
Daily briefHealthcare· Money365.Market AI ·

Lilly, AbbVie Expand Portfolios; Eye-Drug Data Hits Regeneron

Eli Lilly advances diabetes and cancer programs while AbbVie wins Parkinson's approval; Regeneron faces competitive pressure from Kodiak readout

FDA & Regulation

Neutral
ABBVLLYMRK
AbbVie (ABBV) received U.S. FDA approval for JUVMO (tavapadon) tablets, the first and only selective D1/D5 receptor agonist for adults with Parkinson's disease, offering a new mechanism to manage motor symptoms alongside existing levodopa-based regimens. The approval adds a differentiated approach within the company's neuroscience portfolio, potentially helping clinicians manage levodopa dose escalation and treatment-related complications in Parkinson's care.
Eli Lilly (LLY) received FDA Breakthrough Therapy designation for its next-generation KRAS G12C inhibitor olomorasib in advanced pancreatic cancer, marking a potential expansion into a difficult-to-treat malignancy. The company also secured U.S. FDA approval for Onswik, a once-weekly basal insulin for adults with type 2 diabetes, and expanded Olumiant's label to treat adolescents 12 and older with severe alopecia areata, supported by large Phase 3 programs showing efficacy and consistent safety profiles.
Merck (MRK) and Daiichi Sankyo voluntarily withdrew the U.S. application for ifinatamab deruxtecan in adults whose extensive-stage small-cell lung cancer progressed during or after platinum-based chemotherapy. Following FDA discussions, the partners said the submitted evidence, including Phase 2 results, did not satisfy accelerated-approval requirements.

Big Pharma & Biotech

Neutral
LLYREGNAMGN
Eli Lilly (LLY) announced results from a new analysis showing that Foundayo (orforglipron) 17.2 mg was associated with significantly greater weight loss and better blood sugar control than oral semaglutide 25 mg in adults with type 2 diabetes. The findings, based on an indirect treatment comparison of Foundayo 17.2 mg against oral semaglutide 25 mg, drew on data from ACHIEVE-3 and PIONEER PLUS and were presented at the 62nd Annual European Association for the Study of Diabetes.
Regeneron Pharmaceuticals (REGN) faces fresh pressure after Kodiak Sciences reported new Phase 3 data on its eye drugs; Kodiak said Zenkuda and tabirafusp alfa tedromer matched Eylea on primary Phase 3 endpoints for macular degeneration treatment. The trial reported similar vision outcomes with Kodiak's candidates given roughly every six months versus Eylea's current eight week dosing interval, introducing competitive dynamics in the ophthalmology franchise.
Amgen (AMGN) announced positive topline Phase 3 results for dazodalibep in systemic Sjögren's disease, with the trial meeting its primary endpoint and demonstrating statistically significant and clinically meaningful improvements in systemic disease activity. Following the announcement, Citi reaffirmed a Neutral rating and $405 price target on the company, noting that while the results were positive, further analysis of the data would inform commercial potential.

Clinical Development & Partnerships

Neutral
MRKREGN
Cyprumed GmbH, a dedicated oral drug delivery company specializing in innovative oral peptide formulations, announced that Merck (MRK) initiated a Phase I clinical trial evaluating a proprietary drug candidate formulated using Cyprumed's oral tablet technology, marking the first Cyprumed technology program to enter human clinical development. The milestone triggers a payment to Cyprumed under the companies' existing collaboration agreement.
Regeneron Pharmaceuticals (REGN) is back in focus after Biohaven entered a new clinical supply agreement to pair BHV-1530 with Regeneron's cancer drug Libtayo in patients with solid tumors, with enrollment in the combination cohort already underway. The collaboration expands potential uses for Libtayo beyond its current indications.

Small Molecule Market (2030 proj.)

$100B
GILDMRKPFE
The global small molecule drug discovery market was valued at $61.5 billion in 2024 and is projected to reach $100 billion by 2030, according to a new strategic business report profiling AstraZeneca, Gilead Sciences (GILD), Merck (MRK) and Pfizer (PFE). AI, computational design and high-throughput screening are accelerating discovery, while targeted therapies, outsourcing and Asia-Pacific expansion create opportunities for growth across the sector.

Looking Ahead

Bullish

ABBV YTD Return

16.12%

ABBV 1Y Total Return

23.02%
LLYABBV
Eli Lilly (LLY) CEO signaled a shift toward larger acquisitions in new therapeutic areas that extend beyond the firm's current obesity focus, indicating a strategic pivot as the company broadens its pipeline and commercial reach through research collaborations, manufacturing expansion and AI-enabled discovery efforts. The company also launched a global Change the Course program aimed at broadening access to its diabetes and obesity treatments in low and middle income countries.
AbbVie (ABBV) continues to build momentum with recent approvals for JUVMO alongside existing franchises including RINVOQ, contributing to a year-to-date gain of 16.12% and a total shareholder return of 23.02% over one year. Analysts are watching how JUVMO's differentiated mechanism will perform in a competitive Parkinson's treatment landscape and whether it can help offset future patent expiries.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy